China overtakes the United States as the leading clinical-trial venue

China has moved ahead of the United States as the leading location for clinical trials, according to a Senate report and a House hearing cited in a newspaper column.¹ The reports raised concern about the change, but the available account gives no trial totals or margin showing how large the lead is.¹ The column’s central distinction is that hosting more trials does not establish that a country is originating the most important medicines.¹ It defines innovation more narrowly, as creating drug targets or technologies that are first of their kind, rather than simply running studies.¹ That difference matters to the argument: China’s expanded role in testing is presented as a competitive shift, not proof that its drugs are clinically superior.¹

The account attributes China’s pace in part to developers’ ability to take drug candidates into human studies and obtain initial clinical evidence sooner than most U.S. companies.¹ Such early results can help developers learn sooner whether a candidate merits further investment, the column argues.¹ The author says that faster learning can spare years of work and hundreds of millions of dollars in investment.¹ Those potential savings are weighed against concerns that speed and careful safeguards may pull in different directions once medicines are tested in people.¹ The column says Chinese studies may follow less extensive safety work before human testing and may select participants in ways that limit the breadth of the resulting evidence.¹

If trial participants do not reflect a wide range of people, the findings may be less useful for predicting how a medicine will work across different populations.¹ The source does not provide participant counts or demographic breakdowns, so it does not quantify the extent of this concern.¹ The author also says Chinese developers have produced medicines closely resembling existing products, along with incremental variations on them.¹ In the author’s assessment, none has yet established clinical superiority as a genuinely first-in-class drug.¹ This is the basis for separating leadership in the number or location of trials from leadership in originating medicines with distinct clinical value.¹

The column points to obesity medicines based on GLP-1 and cancer treatments aimed at HER2, TROP2 and B7H3 as areas crowded with competing development efforts.¹ It says the unmet medical need in those fields is diminishing, framing further activity there as less consequential than progress in areas where needs remain unmet.¹ The source provides no comparative trial totals for those targets, so their mention illustrates the author’s argument rather than measuring China’s overall contribution.¹ The column’s proposed test of innovation is whether developers originate new targets and technologies, not whether they add studies to already busy fields.¹ That framework does not deny China’s growing trial role; it cautions against treating trial activity alone as evidence of breakthrough medicines.¹

The security argument also reaches beyond clinical research to the ingredients used in medicines sold in the United States.¹ The column says Chinese-sourced ingredients go into as many as 90 percent of widely used U.S. medicines, naming ibuprofen and acetaminophen as examples.¹ That figure describes the share of medicines said to use ingredients from China; it is not a count of clinical trials or a measure of drug innovation.¹ The author reports that a Commerce Department inquiry identified this dependence as a national-security risk.¹ The column links that finding to a presidential tariff proclamation issued in April 2026, making medicine supply part of the policy debate around China.¹

The column places this U.S. reliance alongside a Chinese push for greater domestic capacity in pharmaceuticals and medical devices.¹ It says Xi Jinping called for self-sufficiency after foreign companies had dominated China’s higher-end markets in those sectors.¹ Separate concerns focus on genetic information: Washington put BGI subsidiaries on the Commerce Department’s Entity List, partly over fears that such data could reach Chinese military research.¹ The Intelligence Authorization Act assigns U.S. intelligence agencies a role in supporting assessments of China’s efforts to obtain data.¹ The author adds that rules on cross-border movement of data connected to Chinese trials apply in both countries.¹

A broader warning comes from the National Security Commission on Emerging Biotechnology, which said China was advancing quickly toward a leading position in biotechnology.¹ The commission also warned that biotechnology could become part of China’s military modernization.¹ Its concern included the possibility of soldiers enhanced through genetic means and China’s stated aim of building a “world-class” military by 2049.¹ These issues extend the security debate from where trials take place and where ingredients come from to how genetic data might be used.¹ The column therefore presents trial leadership as one part of a wider set of concerns, rather than as the sole measure of biotechnology competition.¹

The author’s proposed response is to make U.S. drug development faster and less expensive, including by simplifying work before human trials.¹ The proposals also include easing regulatory requirements in Phase 1 and Phase 2 and reconsidering how many participants and endpoints studies need.¹ These are recommendations in the column, not evidence that the United States has adopted the changes or that they would produce a particular result.¹ Japan offers another example of an effort to speed development: the column says it has created an office focused on development, startup financing and trials alongside its counterpart to the FDA.² That example places the U.S. proposals in a wider contest over development systems, while the source supplies no figures comparing their costs or outcomes.¹²

Other reports describe security concerns involving China that are separate from clinical trials and pharmaceutical supply.¹³⁴⁵ A U.S. Defence Intelligence Agency report set out a timeline in which China might deploy directed-energy weapons in orbit by the end of the 2020s.³ Victoria Samson of the Secure World Foundation said she would be greatly surprised if China had space-based laser weapons by the late 2020s.³ The account says China already has ground-based energy weapons that can interfere with satellites, with their capabilities expected to grow by the end of the 2020s.³ Brendan Mulvaney said satellite disruption could affect U.S. forces more heavily than the People’s Liberation Army because the United States relies more on space, particularly in a Taiwan conflict.³

A separate report says China’s military announced that naval and air units carried out readiness patrols near Scarborough Shoal on Friday.⁴ The military described the patrols as an effort to reinforce control of the area’s airspace and waters and to oppose what it called rights violations and provocations.⁴ China and the Philippines exchanged accusations around the end of a two-day ASEAN defence ministers’ meeting on Thursday, according to the report.⁴ In climate diplomacy, attention is turning to COP31 in Turkey and the position China will take in negotiations.⁵ At COP30, China helped establish a dialogue on climate-linked unilateral trade measures and a two-year programme concerning climate finance.⁵ China’s environment vice-minister Li Gao said the country would support an open and effective trade system that helps clean-energy technologies spread.⁵